Evidence map›Paper›PMID 24489714›Full record

ArticlePloS one2014

Patient retention, clinical outcomes and attrition-associated factors of HIV-infected patients enrolled in Zimbabwe's National Antiretroviral Therapy Programme, 2007-2010.

Tsitsi Mutasa-Apollo, Ray W Shiraishi, Kudakwashe C Takarinda, Janet Dzangare, Owen Mugurungi, Joseph Murungu, Abu Abdul-Quader, Celia J I Woodfill

Abstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Observational
  17. Observational
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tsitsi Mutasa-ApolloAIDS and TB Department, Zimbabwe Ministry of Health and Child Care, Harare, Zimbabwe.
Ray W ShiraishiDivision of Global HIV/AIDS, Center for Global Health, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, United States of America.
Kudakwashe C TakarindaAIDS and TB Department, Zimbabwe Ministry of Health and Child Care, Harare, Zimbabwe.
Janet DzangareAIDS and TB Department, Zimbabwe Ministry of Health and Child Care, Harare, Zimbabwe.
Owen MugurungiAIDS and TB Department, Zimbabwe Ministry of Health and Child Care, Harare, Zimbabwe.
Joseph MurunguAIDS and TB Department, Zimbabwe Ministry of Health and Child Care, Harare, Zimbabwe.
Abu Abdul-QuaderDivision of Global HIV/AIDS, Center for Global Health, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, United States of America.
Celia J I WoodfillDivision of Global HIV/AIDS, Centers for Disease Control and Prevention (CDC), Accra, Ghana.

Funding

PEPFAR
6 · The paper itself

Abstract

backgroundSince establishment of Zimbabwe's National Antiretroviral Therapy (ART) Programme in 2004, ART provision has expanded from <5,000 to 369,431 adults by 2011. However, patient outcomes are unexplored.

objectiveTo determine improvement in health status, retention and factors associated with attrition among HIV-infected patients on ART.

methodsA retrospective review of abstracted patient records of adults ≥ 15 years who initiated ART from 2007 to 2009 was done. Frequencies and medians were calculated for rates of retention in care and changes in key health status outcomes at 6, 12, 24 and 36 months respectively. Cox proportional hazards models were used to determine factors associated with attrition.

resultsOf the 3,919 patients, 64% were female, 86% were either WHO clinical stage III or IV. Rates of patient retention at 6, 12, 24 and 36 months were 90.7%, 78.1%, 68.8% and 64.4%, respectively. After ART initiation, median weight gains at 6, 12, and 24 months were 3, 4.5, and 5.0 kgs whilst median CD4+ cell count gains at 6, 12 and 24 months were 122, 157 and 279 cells/µL respectively. Factors associated with an increased risk of attrition included male gender (AHR 1.2; 95% CI, 1.1-1.4), baseline WHO stage IV (AHR 1.7; 95% CI, 1.1-2.6), lower baseline body weight (AHR 2.0; 95% CI, 1.4-2. 8) and accessing care from higher level healthcare facilities (AHR 3.5; 95% 1.1-11.2).

conclusionsOur findings with regard to retention as well as clinical and immunological improvements following uptake of ART, are similar to what has been found in other settings. Factors influencing attrition also mirror those found in other parts of sub-Saharan Africa. These findings suggest the need to strengthen earlier diagnosis and treatment to further improve treatment outcomes. Whilst decentralisation improves ART coverage it should be coupled with strategies aimed at improving patient retention.

Indexed as

Drug MonitoringHIVAdultAnti-HIV AgentsCD4 Lymphocyte CountFemaleHIV InfectionsHumansMaleMiddle AgedPatient DropoutsProportional Hazards ModelsRetrospective StudiesRisk FactorsTreatment OutcomeZimbabweAnti-HIV Agents

Identifiers

PMID24489714
PMCPMC3906052

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.